University of california san diego's herbert wertheim school of public health and human longevity science, University

London, April 13 German researchers have developed a new Covid vaccine that is effective among people with weaker immune systems like cancer patients, particularly those with B-cell deficiencies.B cells are the immune cells responsible for antibody-mediated responses, which is the main target of all currently approved Covid vaccines. But cancer patients remain immunocompromised as treatments such as chemotherapies and some immunotherapies destroy B cells.The results presented at the recent AACR Annual Meeting 2022, showed that the vaccine CoVac-1 induced T-cell immune responses in 93 per cent of patients with B-cell deficiencies, including many patients with leukaemia and lymphoma."To our knowledge, CoVac-1 is currently the only peptide-based vaccine candidate specifically developed and evaluated for immunocompromised patients," said Juliane Walz, Professor at the University Hospital Tubingen in Germany.The CoVac-1 vaccine enhances the response from T cells - another type of immune cell, and "previous evidence has shown that T cells can combat Covid-19 even in the absence of neutralising antibodies," said Claudia Tandler, a graduate student at the University. "T-cell immune responses against SARS-CoV-2 are of particular importance for patients with B-cell deficiencies, who develop very limited antibody responses after infection or vaccination," Tandler added.To develop CoVac-1, Tandler and team chose six specific antigens from different parts of the virus (not limited to spike protein as the current vaccines) to make up their vaccine.CoVac-1 is a peptide vaccine, meaning that the protein pieces are injected directly, rather than being encoded via mRNA."CoVac-1-induced T-cell immunity is far more intense and broader, as it is directed to different viral components than mRNA-based or adenoviral vector-based vaccines that are limited to the spike protein and are thus prone to loss of activity due to viral mutations," Tandler said.In the phase I clinical trial, the researchers recruited 14 patients with a B-cell deficiency, including 12 patients with leukemia or lymphoma. The patients were given a single dose of CoVac-1 and monitored for up to six months for safety and immunogenicity. Notably, 64 per cent of the patients in this study had been previously vaccinated with an approved SARS-CoV-2 vaccine that failed to elicit a humoral immune response.Fourteen days after vaccination, T-cell immune responses were observed in 71 per cent of patients, which rose to 93 per cent of patients, 28 days after vaccination.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

University Of California San Diego's Herbert Wertheim School Of Public Health And Human Longevity ScienceFOLLOW

University of california san diego's herbert wertheim school of public health and human longevity science, Latest News

New York, May 1 Scientists have created the next generation of wearable health sensors that may be able ... ...

Vice President M Venkaiah Naidu on Sunday called for taking higher education into the rural areas and making it more inclusive and equitable. ...

In the wake of a deadly attack inside the premises of Pakistan's Karachi University that left three Chinese nationals among 4 killed, the University has decided to remain suspended for Wednesday. ...

Chinese Embassy in Pakistan condemned the blast inside the premises of a University in Karachi in which three of its nationals were among the four who were killed in Tuesday's explosion. ...

Pakistan Prime Minister Shehbaz Sharif Tuesday condemned the blast inside the premises of a University in Karachi and assured that the "perpetrators will surely be brought to justice." ...

Deakin University, Australia, has announced its Vice-Chancellor's Meritorious Scholarship program 2022, which offers a 100 per cent tuition fee waiver to four high-achieving Indian students for the full duration of their studies at the University - a ...

Aurangabad, April 13: Maharashtra University of Health Sciences (MUHS) launched the summer internship-2022 scheme for the first, second and ... ...

London, April 13 German researchers have developed a new Covid vaccine that is effective among people with weaker ... ...